EUVIMEDEUVIMED entdecken
Crossref

Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing

Johannes F Fahrmann, Michele Yip-Schneider, Jody Vykoukal, Rachelle Spencer, Jennifer B Dennison, Kim-Anh Do, James P Long, Anirban Maitra, Jianjun Zhang, C Max Schmidt, Samir Hanash, Ehsan Irajizad

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Johannes F Fahrmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Early Detection of Cancer. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the current study, we assessed whether repeated measurements of a panel of protein biomarkers with relevance to pancreatic ductal adenocarcinoma (PDAC) improves lead time performance for earlier detection over a single timepoint measurement. Specifically, CA125, CEA, LRG1, REG3A, THBS2, TIMP1, TNRFSF1A as well as CA19-9 were assayed in serially collected pre-diagnostic plasma from 242 PDAC cases and 242 age- and sex-matched non-case control participants in the PLCO cohort. We compared performance estimates of a parametric empirical Bayes (PEB) algorithm, which incorporates participant biomarker history, to that of a single-threshold (ST) method. We demonstrated improvements in AUC estimates (2-13 %) for all biomarkers when considering the PEB approach compared to ST. For CA19-9, the PEBCA19-9 yielded an AUC of 0.88 when at least one repeat measurement was within 3 years of clinical diagnosis. At a specificity of 98.5 %, the PEBCA19-9 identified 15 of the 41 PDAC cases and signaled positive at an average lead-time of 1.09 years whereas the ST approach captured 11 of the 41 PDAC cases with an average positive signal at 0.48 years. Among CA19-9 low individuals, a PEB algorithm based on repeat measurements of TIMP1 yielded an additional 14 % sensitivity at 98.5 % specificity. An adaptive algorithm that considers repeated CA19-9 measurements improves sensitivity and lead-time detection of PDAC compared to a single-threshold method. Additional protein biomarkers may improve sensitivity for earlier detection of PDAC among cases with low CA19-9.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorPancreatic NeoplasmsCarcinoma, Pancreatic DuctalEarly Detection of CancerHumansFemaleMaleMiddle AgedAgedAlgorithmsCA-19-9 AntigenCase-Control StudiesBayes TheoremTissue Inhibitor of Metalloproteinase-1

Stichwörter der Autor:innen

BiomarkerCancer early detectionLongitudinal analysisPancreatic ductal carcinoma

Substanzen

Biomarkers, TumorCA-19-9 AntigenTissue Inhibitor of Metalloproteinase-1

Autor:innen und Institutionen

  • Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 77030.
  • Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 77030.
  • Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA. Electronic address: JZ21@iu.edu.
  • Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: maxschmi@iupui.edu.

Zitieren

APA

Fahrmann, J. F., Yip-Schneider, M., Vykoukal, J., Spencer, R., Dennison, J. B., Do, K. A., Long, J. P., Maitra, A., Zhang, J., Schmidt, C. M., Hanash, S., & Irajizad, E. (2025). Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217450

Vancouver

Fahrmann JF, Yip-Schneider M, Vykoukal J, Spencer R, Dennison JB, Do KA, et al. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217450

BibTeX
@article{Fahrmann2025,
  author = {Fahrmann, Johannes F and Yip-Schneider, Michele and Vykoukal, Jody and Spencer, Rachelle and Dennison, Jennifer B and Do, Kim-Anh and Long, James P and Maitra, Anirban and Zhang, Jianjun and Schmidt, C Max and Hanash, Samir and Irajizad, Ehsan},
  title = {Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217450}
}
Kostenlos starten →